Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Astellas Pharma Inc |
---|---|
Information provided by: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00239265 |
The purpose of this study is to determine whether Tamuslosin is effective in the treatment of lower urinary tract syndrome with female patients.
Condition | Intervention | Phase |
---|---|---|
Urinary Tract Diseases |
Drug: Tamuslosin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 20 Years to 90 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Japan | |
Hokkaido region, Japan | |
Touhoku region, Japan | |
Chubu region, Japan | |
Kyushu region, Japan | |
Chugoku region, Japan | |
Kinki region, Japan |
Study Chair: | Study Director | Clinical Development, Astellas Pharma Inc. |
Study ID Numbers: | B6171/LCT2 |
Study First Received: | September 13, 2005 |
Last Updated: | October 18, 2007 |
ClinicalTrials.gov Identifier: | NCT00239265 History of Changes |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
tamsulosin urinary tract diseases female |
Urologic Diseases Tamsulosin |
Urologic Diseases |